PCM
AUTL

Penserra Capital Management’s Autolus Therapeutics AUTL Stock Holding History

Penserra Capital Management’s Portfolio AUTL Stock Details AUTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-1,305
Closed -$8K – 1379
2021
Q3 		$8K Buy
1,305
+75
+6% +$474 ﹤0.01% 1377
2021
Q2 		$8K Buy
1,230
+460
+60% +$2.85K ﹤0.01% 1285
2021
Q1 		$4K Sell
770
-25
-3% -$185 ﹤0.01% 1091
2020
Q4 		$7K Buy
795
+511
+180% +$5.45K ﹤0.01% 957
2020
Q3 		$3K Buy
+284
New +$4.12K ﹤0.01% 883

Other funds holding AUTL

Blackstone Inc
Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return
SP
Syncona Portfolio St Peter Port, Guernsey $25.7M AUM 13.32% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
FM
Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
TAM
TFG Asset Management Grand Cayman, Cayman Islands $515M AUM 24.47% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Schroder Investment Management Group
Schroder Investment Management Group London, United Kingdom $122B AUM 29.27% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PG
Pendal Group Sydney, Australia $11.6B AUM 12.87% 1-Year Est. Return

Penserra Capital Management's AUTL Position: Q4 2021 in Review

Penserra Capital Management sold out of Autolus Therapeutics (AUTL) in Q4 2021, closing a stake of 1,305 shares — an estimated $8K sold.

Penserra Capital Management first reported a position in AUTL in Q3 2020 and held it in 5 quarters. The position peaked at $8K in Q3 2021. 73 funds tracked by Wall St. Rank hold AUTL as of Q4 2021.

  • Penserra Capital Management reported no remaining Autolus Therapeutics position as of Q4 2021 after selling out during the quarter.
  • Penserra Capital Management sold 1,305 Autolus Therapeutics shares in Q4 2021, an estimated $8K.
  • Penserra Capital Management first reported a position in Autolus Therapeutics in Q3 2020 and held it in 5 quarters.
  • Penserra Capital Management's Autolus Therapeutics position peaked at $8K in Q3 2021.
  • 73 funds tracked by Wall St. Rank held Autolus Therapeutics as of Q4 2021.

Based on Penserra Capital Management's 13F filing for Q4 2021, filed 15 Feb 2022.